Adjuvant PD ‐1 inhibitor versus high‐dose interferon α‐2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis
Author:
Affiliation:
1. Biotherapy Center Sun Yat‐sen University Cancer Center Guangzhou China
2. Biotherapy Center State Key Laboratory of Oncology in South China Guangzhou China
3. Biotherapy Center Collaborative Innovation Center for Cancer Medicine Guangzhou China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15067
Reference28 articles.
1. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?
2. Trends in incidence of thick, thin and in situ melanoma in Europe
3. Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
4. Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)
5. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adjuvant Therapy Using Dabrafenib plus Trametinib in Chinese Patients with Resected Stage III Melanoma: A Multicenter Retrospective Cohort Study;Dermatologic Therapy;2024-05-24
2. Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance;Cancers;2024-04-19
3. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma;International Immunopharmacology;2023-11
4. Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study;Pharmaceuticals;2022-12-28
5. Correction to “Adjuvant PD ‐1 inhibitor versus high‐dose interferon α‐2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis”;Dermatologic Therapy;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3